Logo image of CSU

Capital Senior Living Corp (CSU) Stock Fundamental Analysis

NYSE:CSU - New York Stock Exchange, Inc. -

33.54  -0.72 (-2.09%)

Fundamental Rating

1

Overall CSU gets a fundamental rating of 1 out of 10. We evaluated CSU against 102 industry peers in the Health Care Providers & Services industry. CSU may be in some trouble as it scores bad on both profitability and health. CSU has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year CSU has reported negative net income.
CSU Yearly Net Income VS EBIT VS OCF VS FCFCSU Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 0 -100M -200M

1.2 Ratios

Industry RankSector Rank
ROA -21.75%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CSU Yearly ROA, ROE, ROICCSU Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 0 100 -100 -200

1.3 Margins

The Operating Margin and Gross Margin are not available for CSU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) -49.97%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CSU Yearly Profit, Operating, Gross MarginsCSU Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 0 -20 -40 -60

1

2. Health

2.1 Basic Checks

The number of shares outstanding for CSU remains at a similar level compared to 1 year ago.
CSU has a worse debt/assets ratio than last year.
CSU Yearly Shares OutstandingCSU Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 500K 1M 1.5M 2M
CSU Yearly Total Debt VS Total AssetsCSU Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 200M 400M 600M 800M 1B

2.2 Solvency

CSU has an Altman-Z score of -1.29. This is a bad value and indicates that CSU is not financially healthy and even has some risk of bankruptcy.
A Debt/Equity ratio of -2.98 indicates that CSU is not too dependend on debt financing.
Industry RankSector Rank
Debt/Equity -2.98
Debt/FCF N/A
Altman-Z -1.29
ROIC/WACCN/A
WACCN/A
CSU Yearly LT Debt VS Equity VS FCFCSU Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 0 200M -200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 0.11 indicates that CSU may have some problems paying its short term obligations.
CSU has a Quick Ratio of 0.11. This is a bad value and indicates that CSU is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.11
CSU Yearly Current Assets VS Current LiabilitesCSU Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 100M 200M 300M

1

3. Growth

3.1 Past

CSU shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -169.26%.
The Revenue for CSU has decreased by -30.87% in the past year. This is quite bad
The Revenue has been decreasing by -1.41% on average over the past years.
EPS 1Y (TTM)-169.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%472.86%
Revenue 1Y (TTM)-30.87%
Revenue growth 3Y-6.32%
Revenue growth 5Y-1.41%
Sales Q2Q%-43.31%

3.2 Future

CSU is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.95% yearly.
Based on estimates for the next years, CSU will show a decrease in Revenue. The Revenue will decrease by -3.59% on average per year.
EPS Next Y127.22%
EPS Next 2Y39.76%
EPS Next 3Y25.31%
EPS Next 5Y13.95%
Revenue Next Year-39.6%
Revenue Next 2Y-18.7%
Revenue Next 3Y-10.67%
Revenue Next 5Y-3.59%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CSU Yearly Revenue VS EstimatesCSU Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
CSU Yearly EPS VS EstimatesCSU Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CSU. In the last year negative earnings were reported.
Also next year CSU is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CSU Price Earnings VS Forward Price EarningsCSU Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 38.81
CSU Per share dataCSU EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 -50 100

4.3 Compensation for Growth

CSU's earnings are expected to grow with 25.31% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.76%
EPS Next 3Y25.31%

0

5. Dividend

5.1 Amount

CSU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

Capital Senior Living Corp

NYSE:CSU (11/12/2021, 8:52:54 PM)

33.54

-0.72 (-2.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins Owners127.24%
Ins Owner Change0%
Market Cap70.07M
Analysts42.5
Price Target23.46 (-30.05%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.24
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 38.81
EPS(TTM)-72.7
EYN/A
EPS(NY)-5.77
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS141.43
BVpS-91.27
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.75%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) -49.97%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity -2.98
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.11
Altman-Z -1.29
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-169.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%472.86%
EPS Next Y127.22%
EPS Next 2Y39.76%
EPS Next 3Y25.31%
EPS Next 5Y13.95%
Revenue 1Y (TTM)-30.87%
Revenue growth 3Y-6.32%
Revenue growth 5Y-1.41%
Sales Q2Q%-43.31%
Revenue Next Year-39.6%
Revenue Next 2Y-18.7%
Revenue Next 3Y-10.67%
Revenue Next 5Y-3.59%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A